Poster
156
(#156) Patient Experience With Once-Daily Deutetrabenazine Extended-Release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use
Psych Congress 2025
Abstract: Background: Deutetrabenazine is used for treatment of tardive dyskinesia (TD) and Huntington disease (HD)-related chorea. A survey study explored patient-reported experience with once-daily (QD) deutetrabenazine extended-release tablets. This subgroup analysis explored responses from participants taking deutetrabenazine QD for their TD who reported prior valbenazine use (PVU).
Methods: This noninterventional, prospective, cross-sectional, IRB-approved survey included adults with TD/HD-related chorea taking deutetrabenazine QD. Participants in the Teva Shared Solutions patient support program who completed/were due for their 12-week nurse outreach phone call were eligible.
Results: 209 participants with TD completed the survey, with 54 participants reporting PVU (mean age 56.7 years, 78% female, 91% White) and 100 participants reporting no prior TD medication (de novo; 61.7 years, 70% female, 97% White). ≥82% of participants in both groups liked that their doctor could adjust their dose. >94% of participants in both groups reported that their extra movements were very much/much/minimally improved with deutetrabenazine QD. In both groups, >77% strongly agreed/agreed that since starting deutetrabenazine QD, reduction in their extra movements had improved their comfort in social settings and emotional well-being. Most participants reported it was very/somewhat easy to take deutetrabenazine QD (PVU: 96%; de novo: 99%) and 96% across groups strongly agreed/agreed that they will continue taking deutetrabenazine QD. 91% (PVU) and 89% (de novo) reported satisfaction with deutetrabenazine QD.
Conclusions: Most participants with TD who reported prior valbenazine use and those who initiated deutetrabenazine QD de novo reported improvements in their extra movements and overall satisfaction with deutetrabenazine QD.
Short Description: Adults with tardive dyskinesia (TD) taking once-daily (QD) deutetrabenazine extended-release tablets completed a survey. This subgroup analysis explored responses from participants with TD who previously reported taking valbenazine before initiating deutetrabenazine QD and those who reported no prior TD medication. Across groups, >94% reported that extra movements were very much/much/minimally improved with deutetrabenazine QD. ≥82% liked that their doctor could adjust their dose. ≥89% reported satisfaction with deutetrabenazine QD; 97% expressed interest in continuing treatment.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
Methods: This noninterventional, prospective, cross-sectional, IRB-approved survey included adults with TD/HD-related chorea taking deutetrabenazine QD. Participants in the Teva Shared Solutions patient support program who completed/were due for their 12-week nurse outreach phone call were eligible.
Results: 209 participants with TD completed the survey, with 54 participants reporting PVU (mean age 56.7 years, 78% female, 91% White) and 100 participants reporting no prior TD medication (de novo; 61.7 years, 70% female, 97% White). ≥82% of participants in both groups liked that their doctor could adjust their dose. >94% of participants in both groups reported that their extra movements were very much/much/minimally improved with deutetrabenazine QD. In both groups, >77% strongly agreed/agreed that since starting deutetrabenazine QD, reduction in their extra movements had improved their comfort in social settings and emotional well-being. Most participants reported it was very/somewhat easy to take deutetrabenazine QD (PVU: 96%; de novo: 99%) and 96% across groups strongly agreed/agreed that they will continue taking deutetrabenazine QD. 91% (PVU) and 89% (de novo) reported satisfaction with deutetrabenazine QD.
Conclusions: Most participants with TD who reported prior valbenazine use and those who initiated deutetrabenazine QD de novo reported improvements in their extra movements and overall satisfaction with deutetrabenazine QD.
Short Description: Adults with tardive dyskinesia (TD) taking once-daily (QD) deutetrabenazine extended-release tablets completed a survey. This subgroup analysis explored responses from participants with TD who previously reported taking valbenazine before initiating deutetrabenazine QD and those who reported no prior TD medication. Across groups, >94% reported that extra movements were very much/much/minimally improved with deutetrabenazine QD. ≥82% liked that their doctor could adjust their dose. ≥89% reported satisfaction with deutetrabenazine QD; 97% expressed interest in continuing treatment.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
